Pediatric Growth Hormone DeficiencyPhase 1/2NCT07450001
A Study of GenSci134 in Children With Growth Hormone Deficiency (PGHD)
A Phase 1/2 study testing GenSci134 Injection and Recombinant Human Growth Hormone Injection(Norditropin® FlexPro®) in people with Pediatric Growth Hormone Deficiency, run by Changchun GeneScience Pharmaceutical Co., Ltd. at 1 site in China.
Trial summary
This study comprises two phases: Phase Ib and Phase II. Phase Ib is a multicenter, randomized, open-label, active-controlled, single-dose, dose-escalation to assess safety, tolerability, PK/PD profile, and immunogenicity of GenSci134 in children with GHD. Read more about this study
- Who is it for?
- Ages 3 to 12 years
- Conditions the study is for
- Pediatric Growth Hormone Deficiency
- What is being tested?
- GenSci134 Injection and Recombinant Human Growth Hormone Injection(Norditropin® FlexPro®)
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 128 participants
- Where
- 1 siteChina
- Study dates
- 6 Mar 2026to 31 Dec 2028
- Phase
- Phase 1/2
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 3 to 12 years
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- Informed consent of parent or legal representative of participant and child assent, as age appropriate must be obtained before any study-related activities.
- At the time of signing the Informed consent form (ICF), the following conditions must be met:
- Phase Ib:
- Girls: age ≥3and ≤11 years, breast development at Tanner stage 1, body weight ≥16 kg; Boys: age ≥3 and ≤12 years, testis volume <4 mL, body weight ≥16 kg.
- Phase II:
- Girls: age ≥3 and ≤9 years, breast development at Tanner stage 1; Boys: age ≥3 and ≤10 years, testis volume <4 mL.
Show all 14Show fewer
- BMI within the range of ±2 SD of the mean BMI for age and sex at screening
- Height is at least 2 SD below the mean HT for age and sex (HT SDS ≤ -2.0) at screening according to the normal pediatric population standards
- Diagnosis of GHD confirmed by two different GH stimulation tests performed at screening or within 12 months prior to screening.
- No prior exposure to GH or IGF-1therapy.
- Absence of intracranial tumor, as confirmed by MRI or CT. Images or scans obtained within 1 year prior to screening can be used as screening data if accompanied by a medical evaluation and conclusion.
- AHV <5 cm/year at screening (Phase II only);
- BA < CA at screening (Phase II only);
- IGF-1 SDS ≤ -1.0 at screening (Phase II only).
Who cannot join
- Presence of one or more pituitary hormone deficiencies in addition to growth hormone deficiency.
- Any suspected or known disease likely to affect growth, or any clinically significant abnormality that would preclude the accurate assessment of standing height (Phase II only), including but not limited to:
- Turner syndrome
- Noonan syndrome
- Laron Syndrome
- Other genetic syndromes with short stature that are caused by chromosomal abnormalities or gene mutations, including but not limited to Prader-Willi syndrome, abnormal SHOX-1 gene analysis, or GH receptor deficiency.
Show all 28Show fewer
- Born small for gestational age
- Growth retardation due to malnutrition
- Growth retardation due to hypothyroidism.
- Short stature with any other clearly identified etiology.
- Congenital abnormalities causing skeletal abnormalities, or claudication (Phase II only).
- Significant spinal abnormalities (Phase II only).
- Epiphyseal closure (Phase II only).
- Abnormal liver function, renal function, or coagulation profile
- Current or prior history of any malignant disease; or a family history of malignancy.
- Presence of impaired glucose metabolism, or HbA1c ≥ 5.7%, or a confirmed diagnosis of diabetes mellitus.
- Clear medical history of cardiovascular, hepatic, renal, gastrointestinal, respiratory, hematological, neurological, or metabolic disorders, or any other condition that, in the opinion of the investigator, makes the participant unsuitable for participation in the study.
- Any clinically significant abnormality in vital signs, physical examinations, laboratory tests, 12-lead ECG, full spine anteroposterior and lateral X-ray, or B-mode ultrasound, other than those associated with the study disease, as judged by the investigator and will make the participant unsuitable for the study.
- A positive result for any of the following serological tests during the screening period: HBsAg, Anti-HCV, Anti-HIV, or TP-Ab.
- Known highly allergic diathesis or hypersensitivity to growth hormone products or any excipient of the investigational drug.
- Participation in another clinical trial within 3 months prior to screening, or if the time since the last dose is less than 5 half-lives of the previous investigational drug at screening.
- Receipt of any blood products within 3 months prior to the first dose, poor peripheral venous access, or any medical condition that will preclude tolerance of the blood sampling procedures.
- Administration of any vaccine within 14 days prior to the first dose or planned vaccination at any time during the study period.
- The participant and/or the parent/legal representative is likely to be non-compliant with respect to study conduct, as judged by the investigator.
- Children have been treated with systemic corticosteroid treatment for longer than 2 consecutive weeks within the last 3 months prior to screening (Phase II only).
- Children have been treated with inhaled glucocorticoid therapy at a dose greater than 400 µg/day of inhaled budesonide or equivalents for longer than 4 consecutive weeks within the last 12 months prior to screening (Phase II only).
- Receipt within 3 months prior to screening or planned use during the study of medications that may interfere with growth or development (Phase II only).
- Any other condition that, in the opinion of the investigator, makes the participant unsuitable for participation in the study.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site
Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology
Wuhan, Hubei, 430000
About this study
Official title: A Phase Ib/II Multicenter, Randomized, Open-label, Active-controlled, Single/Multiple-dose, Dose-finding, Clinical Study of GenSci134 in Children With Growth Hormone Deficiency
This study comprises two phases: Phase Ib and Phase II. Phase Ib is a multicenter, randomized, open-label, active-controlled, single-dose, dose-escalation to assess safety, tolerability, PK/PD profile, and immunogenicity of GenSci134 in children with GHD.
Phase II is a multicenter, randomized, open-label, active-controlled, multiple-dose, parallel-group study to assess the efficacy and safety of multiple subcutaneous doses of GenSci134 at different levels versus Norditropin® in children with GHD. It will also evaluate PK/PD profile and immunogenicity to support dose selection for Phase III.
- Conditions
- Pediatric Growth Hormone Deficiency
- Being tested
- GenSci134 Injection, Recombinant Human Growth Hormone Injection(Norditropin® FlexPro®)
- Keywords
- GenSci134, PGHD
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
GenSci134 InjectionDrug
Also called GenSci134
only one dose of GenSci134 to be given, subcutaneous , 6 dose levels will be assigned.
Recombinant Human Growth Hormone Injection(Norditropin® FlexPro®)Drug
Also called Norditropin®
multiple doses of Norditropin® FlexPro® quaque die (QD) for 28 consecutive days by subcutaneous injections.
| Study group | Role | What they receive |
|---|---|---|
| Dose Level 1~ Dose Level 6 | Experimental | dose level 1、dose level 2、dose level 3、dose level 4、 dose level 5、dose level 6 Receives: Drug: GenSci134 Injection |
| Recombinant Human Growth Hormone Injection (Norditropin®) | Active comparator | Active control group Receives: Drug: Recombinant Human Growth Hormone Injection(Norditropin® FlexPro®) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Phase Ib: Treatment Emergent Adverse Events （TEAEs）
Measured: From the first dose to Day 35
Phase II: Annualized height velocity (AHV) at Week 24 of treatment
Measured: 24 weeks
Secondary outcomes (13)
Phase Ib: Areas under the drug concentration-time curve (AUC0-t, AUC0-∞) of GenSci134
Measured: From Day 1 to Day 29
Phase Ib: Time to maximum concentration (Tmax) of GenSci134
Measured: From Day 1 to Day 29
Phase Ib: Maximum concentration (Cmax) of GenSci134
Measured: From Day 1 to Day 29
Phase Ib: Half-life (t1/2) of GenSci134
Measured: From Day 1 to Day 29
Phase Ib: Serum level of IGF-1 and IGFBP-3 and their changes from baseline.
Measured: From Day 1 to Day 29
Phase Ib: Incidence and timing of positive anti-drug antibody (ADA) and/or neutralizing antibody (NAb) (if applicable)
Measured: From Day 1 to Day 29
Phase II: Change from baseline in HT SDS at each visit
Measured: From baseline to Week 28 of the extension period
Phase II: Change from baseline in AHV at each visit
Measured: From baseline to Week 28 of the extension period
Phase II: Change from baseline in BA/CA at each visit.
Measured: From baseline to Week 28 of the extension period
Phase II: Treatment Emergent Adverse Events（TEAEs）
Measured: From the first dose to Week 29 of the extension period
Phase II: Serum concentration of GenSci134.
Measured: From baseline to Week 28 of the extension period
Phase II: Serum level of IGF-1and IGFBP-3 and their changes from baseline.
Measured: From baseline to Week 28 of the extension period
Phase II: Incidence and timing of positive ADA and/or NAb (if applicable).
Measured: From baseline to Week 28 of the extension period
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Mar 2026
- Study start6 Mar 2026 (estimated)
- Primary completion18 Jul 2028 (estimated)
- Study completion31 Dec 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Pediatric Growth Hormone DeficiencyStudies of the same condition, open and under way.
- More trials run by Changchun GeneScience Pharmaceutical Co., Ltd.The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1/2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Sequential
- Masking
- None (open label)
- Enrolment
- 128 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07450001
- Sponsor's protocol ID
- GenSci134-202
- Status last verified
- Feb 2026
- First submitted
- 12 Feb 2026
- Last updated
- 4 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No